Compare
Beyfortus vs. Abrysvo

Beyfortus (nirsevimab or nirsevimab-alip) is an injection given to babies and children up to 24 months old. It's used to prevent them from getting very sick from respiratory syncytial virus (RSV). It's not an RSV vaccine. Instead, it's a monoclonal antibody that gives protection against the virus for a short time. Beyfortus (nirsevimab) is now part of the CDC Child Immunization Schedule. The usual dosage is 1 to 2 injections into the muscle during or at the start of the RSV season. It's well-tolerated with only a few side effects.

• Prevention of respiratory syncytial virus (RSV) in young children of certain ages
  • Newborns and infants born during or entering their first RSV season
  • Children up to 24 months old at risk of severe RSV illness through their second RSV season

• Side effects aren't common. See Other Side Effects.

• Severe allergic reaction
• Caution use in children with bleeding problems

Abrysvo (RSV vaccine) is a vaccine that helps lower your risk of getting serious lung infections caused by respiratory syncytial virus (RSV). It's FDA approved for adults 60 years and older, and adults 18 to 59 years who have a higher risk of getting seriously ill from RSV. It's also approved for pregnant mothers between 32 and 36 weeks gestation to help protect their babies from RSV after birth. Abrysvo (RSV vaccine) is given as a single injection into the muscle. Common side effects include tiredness, headache, and injection site reactions like pain, swelling, or redness.

Prevention of serious lung infections caused by respiratory syncytial virus (RSV) in:

• Adults 60 years and older
• Adults 18 to 59 years old who have a higher risk of illness due to RSV
• Pregnant mothers between 32 to 36 weeks gestation

18 to 59 years old:

• Tiredness (37%)
• Pain at injection site (35%)
• Headache (28%)
• Muscle pain (24%)
• Diarrhea (15%)
• Joint pain (12%)
• Nausea (12%)

60 years and older:

• Tiredness (16%)
• Headache (13%)
• Pain at injection site (11%)
• Muscle pain (10%)

Pregnant mothers:

• Tiredness (46%)
• Pain at injection site (41%)
• Headache (31%)
• Muscle pain (27%)
• Nausea (20%)

• Guillain‑Barré syndrome
• Potential risk of preterm (early) birth
• Severe allergic reaction
• Fainting
• Weaker vaccine protection